Scotiabank reaffirmed their outperform rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a research note released on Thursday morning. Scotiabank currently has a C$5.00 price objective on the stock.
PLI has been the subject of a number of other research reports. CIBC dropped their target price on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. TD Securities restated a speculative buy rating and set a C$4.50 target price on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Finally, Royal Bank Of Canada restated an outperform rating on shares of ProMetic Life Sciences in a research report on Wednesday, June 15th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) opened at 3.12 on Thursday. ProMetic Life Sciences has a one year low of $1.67 and a one year high of $3.62. The firm has a 50-day moving average of $2.94 and a 200-day moving average of $3.00. The company’s market cap is $1.89 billion.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.